Ontology highlight
ABSTRACT: Background
Tocilizumab (TCZ), an interleukin-6 receptor antibody, has previously been used for treating patients with the coronavirus disease 2019 (COVID-19), but there is a lack of data regarding the administration timing of TCZ.Objectives
This study aimed to evaluate the timing and efficacy of TCZ in the treatment of patients with COVID-19.Methods
Laboratory-confirmed patients with COVID-19 with an elevated interleukin-6 (IL-6) level (>10 pg/ml) were offered TCZ intravenously for compassionate use. Clinical characteristics, laboratory tests, and chest imaging before and after the administration of TCZ were retrospectively analyzed.Results
A total of 58 consecutive patients who met the inclusion criteria and with no compliance to the exclusion criteria were
SUBMITTER: Li P
PROVIDER: S-EPMC8084410 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature